Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Chief Medical Officer | March 12, 2026 | August 07, 2026 |
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Chief Medical Officer | August 15, 2026 | August 18, 2026 |
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | Chief Medical Officer | August 06, 2019 | August 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date March 12, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,667 |
Reported balance
After 2026-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-12 · Grant · Acquired 16,667 · Balance 16,667 F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026. F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3: The PSUs vest and settle over two years; 50% vests on March 12, 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026.
F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
F3: The PSUs vest and settle over two years; 50% vests on March 12, 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date.
First Tracks Biotherapeutics, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 137,651 |
Reported balance
After 2026-08-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 60,492 · Balance 137,651 F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026. F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026.
F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date.
Sienna Biopharmaceuticals, Inc.
Report date August 06, 2019 · Filed August 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 196,488 |
Reported balance
After 2019-08-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-08-06 · Grant · Acquired 55,000 · Balance 196,488 F1: Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date. F2: Includes a total of 5,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.08 · Expires 2028-06-01 | Direct | 0 |
Reported balance
After 2019-08-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-08-06 · Disposition to issuer · Disposed 48,720 · Balance 0 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F5: Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2027-07-26 | Direct | 0 |
Reported balance
After 2019-08-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-08-06 · Disposition to issuer · Disposed 11,926 · Balance 0 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F6: Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2019-08-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-08-06 · Disposition to issuer · Disposed 14,904 · Balance 0 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2019-08-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-08-06 · Disposition to issuer · Disposed 22,500 · Balance 0 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F7: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2019-08-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-08-06 · Disposition to issuer · Disposed 22,500 · Balance 0 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F8: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2027-07-26 | Direct | 11,926 |
Reported balance
After 2019-08-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-08-06 · Grant · Acquired 11,926 · Balance 11,926 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F6: Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2028-06-01 | Direct | 48,720 |
Reported balance
After 2019-08-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-08-06 · Grant · Acquired 48,720 · Balance 48,720 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F5: Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2029-01-01 | Direct | 14,904 |
Reported balance
After 2019-08-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-08-06 · Grant · Acquired 14,904 · Balance 14,904 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2029-01-01 | Direct | 22,500 |
Reported balance
After 2019-08-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-08-06 · Grant · Acquired 22,500 · Balance 22,500 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F7: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2029-01-01 | Direct | 22,500 |
Reported balance
After 2019-08-06 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-08-06 · Grant · Acquired 22,500 · Balance 22,500 F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F8: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,557 |
Reported balance
Holding disclosure · report date 2019-08-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,557 F3: The shares are directly held by Lizzul Living Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date.
F2: Includes a total of 5,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
F3: The shares are directly held by Lizzul Living Trust.
F4: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options.
F5: Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
F6: Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
F7: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
F8: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 18, 2024 Filed Jul 20, 2024 00:35 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 1,500 | $18.50 | $27,750.00 |
DisclosureSEC source: 0001415889-24-019829 · form4-07202024_120740.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the acquisition of 1,500 shares acquired under the Company's ESPP. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 00:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,554 | $21.81 | $55,702.74 |
DisclosureSEC source: 0001209191-24-001280 · doc4.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,118 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 00:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001280 · doc4.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,435 Underlying: Common Stock · 6,145 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 00:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001280 · doc4.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:00 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 42,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001052 · doc4.xml · derivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,220 Underlying: Common Stock · 42,220 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:00 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 115,540 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001209191-24-001052 · doc4.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,540 Underlying: Common Stock · 115,540 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 22:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049810 · doc4.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 22:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,105 | $19.48 | $41,005.40 |
DisclosureSEC source: 0001209191-23-049810 · doc4.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,527 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 22:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-049810 · doc4.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · balance_after: Reflects the acquisition of 881 shares acquired under the Company's ESPP. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 00:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 24,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002880 · doc4.xml · derivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,580 Underlying: Common Stock · 24,580 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 00:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 67,070 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001209191-23-002880 · doc4.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,070 Underlying: Common Stock · 67,070 shares Expires 2033-01-05 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050354 · doc4.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Represents a one-time retention grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 50% of the total RSUs vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: 50% of the total RSUs vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · balance_after: In addition to the remaining options to purchase 12,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 215,000 shares of common stock, which options vest according to their terms, and (ii) 1,751 shares of common stock held directly. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 23:03 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001209191-22-039531 · doc4.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: On February 10, 2021, the reporting person was granted a performance-based option to purchase 10,000 shares of the Issuer's common stock, subject to the achievement of certain corporate performance criteria and the reporting person's continued service to the Issuer upon achievement thereof. The performance criteria were achieved on the date in Column 3, resulting in the vesting of the entire award. F2 · balance_after: In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 205,000 shares of common stock, which options vest according to their terms, and (ii) 1,751 shares of common stock held directly. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:55 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-22-009364 · doc4.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F2 · balance_after: In addition to the remaining options to purchase 70,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 135,000 shares of common stock, which options vest according to their terms, and (ii) 964 shares of common stock held directly. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:22 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantCommon Stock | 964 | $22.03 | $21,236.92 |
DisclosureSEC source: 0001209191-21-065178 · doc4.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 964 F1 · shares: Represents shares of Common Stock acquired pursuant to the Issuer's Employee Stock Purchase Plan ("ESPP"), for the purchase period through November 15, 2021. In accordance with the ESPP, these shares were purchased at 85% of the lesser of the closing price of the Issuer's Common Stock on May 17, 2021 and November 15, 2021. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 02:42 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001209191-21-010533 · doc4.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2022, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 20:18 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $18.50 | $0.00 |
DisclosureSEC source: 0001209191-20-044259 · doc4.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2030-07-30 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:40 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.71 | Not disclosed |
DisclosureSEC source: 0001562180-19-004217 · primarydocument.xml · derivative · entry 12 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-01-01 F4 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F8 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:40 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.71 | Not disclosed |
DisclosureSEC source: 0001562180-19-004217 · primarydocument.xml · derivative · entry 11 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-01-01 F4 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F7 · derivative.exercise_date: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:40 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 14,904 | Not disclosed Strike: $0.71 | Not disclosed |
DisclosureSEC source: 0001562180-19-004217 · primarydocument.xml · derivative · entry 10 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,904 Underlying: Common Stock · 14,904 shares Expires 2029-01-01 F4 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:40 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 48,720 | Not disclosed Strike: $0.71 | Not disclosed |
DisclosureSEC source: 0001562180-19-004217 · primarydocument.xml · derivative · entry 9 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,720 Underlying: Common Stock · 48,720 shares Expires 2028-06-01 F4 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F5 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:40 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 11,926 | Not disclosed Strike: $0.71 | Not disclosed |
DisclosureSEC source: 0001562180-19-004217 · primarydocument.xml · derivative · entry 8 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,926 Underlying: Common Stock · 11,926 shares Expires 2027-07-26 F4 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F6 · derivative.exercise_date: Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:40 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Disposition to issuerStock Options (Right to buy) · Derivative | 22,500 | Not disclosed Strike: $2.32 | Not disclosed |
DisclosureSEC source: 0001562180-19-004217 · primarydocument.xml · derivative · entry 7 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2029-01-01 F4 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F8 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:40 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Disposition to issuerStock Options (Right to buy) · Derivative | 22,500 | Not disclosed Strike: $2.32 | Not disclosed |
DisclosureSEC source: 0001562180-19-004217 · primarydocument.xml · derivative · entry 6 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2029-01-01 F4 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F7 · derivative.exercise_date: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:40 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Disposition to issuerStock Options (Right to buy) · Derivative | 14,904 | Not disclosed Strike: $2.32 | Not disclosed |
DisclosureSEC source: 0001562180-19-004217 · primarydocument.xml · derivative · entry 5 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,904 shares Expires 2029-01-01 F4 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:40 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Disposition to issuerStock Options (Right to buy) · Derivative | 11,926 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001562180-19-004217 · primarydocument.xml · derivative · entry 4 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,926 shares Expires 2027-07-26 F4 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F6 · derivative.exercise_date: Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:40 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Disposition to issuerStock Options (Right to buy) · Derivative | 48,720 | Not disclosed Strike: $15.08 | Not disclosed |
DisclosureSEC source: 0001562180-19-004217 · primarydocument.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,720 shares Expires 2028-06-01 F4 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F5 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:40 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantCommon Stock | 55,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-19-004217 · primarydocument.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,488 F1 · price: Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date. F2 · balance_after: Includes a total of 5,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 17:39 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Tax withholdingCommon Stock | 4,095 | $0.76 | $3,112.20 |
DisclosureSEC source: 0001562180-19-003850 · primarydocument.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,488 F1 · shares: Represents shares otherwise issuable to the Reporting Person that were withheld to satisfy the Issuer's tax withholding obligation upon settlement of restricted stock units. F2 · price: This transaction was executed in multiple trades in prices ranging from $0.72 to $0.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes a total of 5,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 23:16 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 22,500 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001562180-19-000148 · primarydocument.xml · derivative · entry 5 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 22,500 shares Expires 2029-01-01 F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 23:16 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 22,500 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001562180-19-000148 · primarydocument.xml · derivative · entry 4 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-01-01 F4 · derivative.exercise_date: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 23:16 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 14,904 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001562180-19-000148 · primarydocument.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,904 Underlying: Common Stock · 14,904 shares Expires 2029-01-01 Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 23:16 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantCommon Stock | 45,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-19-000148 · primarydocument.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,583 F1 · price: Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to twenty-five percent (25%) of the total number of RSUs on July 1, 2019, twenty-five percent (25%) of the total number of RSUs on January 1, 2020, and the remaining fifty percent (50%) of the total number of RSUs on the second anniversary, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date. F2 · balance_after: Includes a total of 2,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 01:28 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 48,720 | $0.00 Strike: $15.08 | $0.00 |
DisclosureSEC source: 0001562180-18-002842 · primarydocument.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,720 Underlying: Common Stock · 48,720 shares Expires 2028-06-01 F3 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 20:23 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionSeries A-3 Preferred Stock · Derivative | 10,557 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029595 · doc1.xml · derivative · entry 3 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 10,557 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.nature: The shares are directly held by the Lizzul Living Trust, Paul F. Lizzul and Dawn Marie Lizzul, Trustees. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 20:23 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | PurchaseCommon Stock | 10,000 | $15.00 | $150,000.00 |
DisclosureSEC source: 0001140361-17-029595 · doc1.xml · nonDerivative · entry 2 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,634 F3 · kind: The Reporting Person purchased the shares of the Issuer's common stock in connection with the Issuer's initial public offering at the offering price of $15.00 per share. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 20:23 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionCommon Stock | 10,557 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029595 · doc1.xml · nonDerivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: The shares are directly held by the Lizzul Living Trust, Paul F. Lizzul and Dawn Marie Lizzul, Trustees. Read SEC document |
| July 26, 2017 Filed Jul 27, 2017 20:26 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Option (Right to Buy) · Derivative | 11,926 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-17-028901 · doc1.xml · derivative · entry 1 Lizzul Paul F. · CIK 0001711462 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,926 Underlying: Common Stock · 11,926 shares Expires 2027-07-26 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.